ELI LILLY & CO shares rose 4% on Monday afternoon following positive clinical trial data for its next-generation obesity treatment, retatrutide. The stock has gained 9% this year, while rival NOVO NORDISK A/S-B fell roughly 17% year-to-date. Investors view the drug as a catalyst to solidify ELI LILLY & CO dominance in a market projected to exceed $200 billion.

Retatrutide Matches Zepbound Efficacy at Lower Doses